More good news from BCW member Regeneron Pharmaceuticals which this week released a new analysis of data showing that its monoclonal antibody cocktail known as REGEN-COV is effective against Covid-19 infection. Positive results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases showed that the drug reduces by 81.6% the risk of being infected by the Covid-19 virus, SARS-CoV-2. The data are from an ongoing clinical trial in which a group of participants received a 1,200-milligram dose of the drug in four injections administered under the skin. The clinical trial involved 1,683 people who were […]